UBS Maintains Neutral on Aveanna Healthcare Hldgs, Raises Price Target to $13

Benzinga Newsdesk www.benzinga.com Positive 71.8%

Neg 0% Neu 0% Pos 71.8%

UBS analyst A.J. Rice maintains Aveanna Healthcare Hldgs (NASDAQ:AVAH) with a Neutral and raises the price target from $8 to $13.